Vital Therapies Announces Management Addition; Enrollment in VTI-208 Phase 3 Trial Now 75 Percent Complete
September 08, 2014 08:00 ET
|
Vital Therapies, Inc.
SAN DIEGO, Sept. 8, 2014 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting treatment of acute liver failure, is...
Vital Therapies Announces Second Quarter 2014 Financial Results and Provides Update on Operations and Upcoming Conference Presentations
August 06, 2014 16:34 ET
|
Vital Therapies, Inc.
SAN DIEGO, Aug. 6, 2014 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute liver failure,...
Vital Therapies Announces Poster Presentation at the 2014 World Transplant Congress
July 28, 2014 16:15 ET
|
Vital Therapies, Inc.
SAN DIEGO, July 28, 2014 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting treatment of acute liver failure,...
Vital Therapies Reports on Clinical Trial Progress and EU Regulatory Advice
July 09, 2014 05:30 ET
|
Vital Therapies, Inc.
SAN DIEGO, July 9, 2014 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting treatment of acute liver failure, is...